News | August 11, 2021
Lupin posts net profit of Rs 542.46 cr. in Q1FY22
The profits were bolstered by the Boehringer Ingelheim MEK program income
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
The drug is indicated for mild and transient episodes of heart block
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Subscribe To Our Newsletter & Stay Updated
